Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes
NCT05134662Phase 1Completed
- Sponsor
- Altimmune, Inc.
- Start
- Feb 2022
- Primary completion
- Feb 2023
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pemvidutide in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by Altimmune, Inc. Primary endpoints: Number of Participants with One or More Treatment-Emergent Adverse Events at Day 110, Changes from baseline in area under the curve of serum glucose, C-peptide, and insulin at Day 85 and 1 more. Started Feb 2022; status: completed.
02
Drugs
pemvidutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05134662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05134662.